Lynkuet (Elinzanetant): What the Trials Showed, Who It Suits, and the Monitoring Nobody Should Skip

What is Lynkuet, and how is it different?

Lynkuet (elinzanetant) is a non-hormonal prescription capsule for moderate to severe hot flashes and night sweats caused by menopause. The FDA approved it on 24 October 2025. It is made by Bayer and taken once daily at bedtime, with or without food.

It is the first and only drug that blocks both the neurokinin 1 and neurokinin 3 receptors. That dual action is the difference from fezolinetant (Veozah), which blocks NK3 alone and reached the market in May 2023. Our page on fezolinetant covers the older option.

How does blocking a receptor stop a hot flash?

As estrogen falls, a cluster of neurons in the hypothalamus that helps regulate body temperature becomes overactive. These neurons signal partly through neurokinin B acting on the NK3 receptor. Blocking that receptor calms the misfiring thermostat, which is how this class reduces hot flashes without using hormones at all.

The NK1 receptor sits in pathways involved in sleep and mood. Blocking it as well is the rationale for why elinzanetant was studied with sleep disturbance as an outcome rather than flush count alone. Whether that produces a meaningful clinical difference against fezolinetant has not been tested head to head, and claiming otherwise would be going beyond the evidence.

How well does it actually work?

Approval rests on three phase 3 trials, OASIS 1, 2 and 3. In OASIS-3, elinzanetant reduced the frequency of moderate to severe vasomotor symptoms by more than 73% at 12 weeks, against 47% on placebo.

Read the placebo number rather than skipping past it. Hot flashes respond substantially to placebo in almost every trial ever run in this symptom, which is why an anecdote from a friend is weak evidence here specifically, and why the controlled comparison is the only number worth quoting. A drug that beats a 47% placebo response by 26 percentage points is doing real work; a drug that produced a 73% response with no comparison arm would tell you nothing.

For context, hormone therapy typically reduces vasomotor symptoms by a larger margin. These drugs exist for women who cannot or will not take estrogen, not as a general first choice. Our comparison of non-hormonal options against HRT sets out that trade directly.

Who is it actually for?

The clearest candidates are women for whom estrogen is off the table:

• A history of breast cancer or another hormone-sensitive cancer. Our page on HRT and breast cancer risk covers where that line sits.
• A history of blood clots or stroke.
• Active liver disease, though note the monitoring requirement below.
• A considered preference against hormone therapy after an informed discussion.

It treats vasomotor symptoms only. It does not protect bone density, and it does not treat genitourinary symptoms such as vaginal dryness or recurrent urinary tract infections. A woman with hot flashes, thinning bone and vaginal dryness has three problems, and this drug addresses one of them.

This table is the argument for why "a non-hormonal option now exists" is not the same sentence as "hormone therapy is no longer needed."

What monitoring does it require?

Liver testing, and this is the step most likely to lapse once a prescription is running smoothly. Expect liver blood tests before starting and repeat testing on the schedule the label specifies during the early months.

Symptoms that warrant a call rather than waiting for the next scheduled draw: unusual tiredness with nausea, loss of appetite, pain in the upper right abdomen, dark urine, pale stools, or yellowing of the skin or eyes. Our guide to liver function tests explains what the numbers on that report mean.

Fezolinetant's label was updated after post-marketing reports of serious liver injury, which is the context for why both drugs in this class carry monitoring requirements. This is the clearest practical line between a prescription NK-receptor antagonist and an over-the-counter supplement marketed for the same symptom.

Lynkuet or Veozah?

There is no head-to-head trial. Choosing between them is currently a conversation about the sleep and mood rationale for NK1 blockade, tolerability, and what your insurance will actually cover.

What will it cost, and what if it does not work?

It is a new branded drug with no generic. Expect prior authorisation from most insurers in the first year, and expect the plan to ask what else has been tried. Manufacturer copay programmes usually exist at launch and are worth asking about directly, as is the specific wording your prescriber uses in the authorisation request. Our page on menopause treatment coverage covers how those requests are usually framed.

Give it the interval your prescriber specifies rather than a fortnight. If flushes are unchanged after an adequate trial, the options are to revisit hormone therapy if it was ruled out for reasons that can be reconsidered, to try the other drug in the class, or to look again at contributors no drug fixes: alcohol, poor sleep, an untreated thyroid problem, or anxiety amplifying the experience of each flush. Our guides to menopause insomnia and non-hormonal options cover those.

What is still unknown?

The trials ran to 52 weeks. Long-term safety beyond that is not established, and neither is use in women with a history of breast cancer specifically, because the trials were not designed to answer that question. A drug containing no hormones is a reasonable thing to discuss with an oncology team, but "non-hormonal" is not the same as "studied in this population."

Real-world tolerability data will also take time. Fezolinetant looked cleaner at approval than it did after post-marketing surveillance, and that sequence is common enough that it is worth knowing you are early in the curve with any 2025 approval.

What happens in the body during a hot flash?

Understanding the mechanism explains why this drug class exists at all, and why it does nothing for the other symptoms of menopause.

The hypothalamus maintains a narrow band of body temperature it will tolerate, sometimes called the thermoneutral zone. In menopause that zone narrows, so a small rise in core temperature that would previously have passed unnoticed now triggers the full heat-loss response: skin vessels dilate, sweating starts, and the sensation arrives as a flush.

A specific population of neurons in the hypothalamus, usually abbreviated KNDy, sits in the middle of this. Estrogen normally restrains them. As estrogen falls they enlarge and become overactive, signalling through neurokinin B onto NK3 receptors. Blocking NK3 quietens that signalling and widens the tolerated temperature band again.

This is why the effect is specific to vasomotor symptoms. Nothing about blocking a hypothalamic receptor restores bone density or vaginal tissue, both of which depend on estrogen acting directly on those tissues.

What are the side effects reported so far?

Commonly reported effects in the OASIS programme were mild and included headache, tiredness and sleepiness, the last unsurprising for a bedtime drug that also acts on sleep pathways. Liver enzyme elevations were the finding that drove the monitoring requirement rather than a symptom most women noticed.

Two caveats about any side-effect list from a registration programme. Trial populations are healthier and more closely monitored than the general population, and rare effects appear only after far larger numbers of people have taken a drug. Fezolinetant illustrates both: its safety profile looked cleaner at approval than it did once post-marketing reports accumulated and the label was updated.

If you are early to a 2025 approval, that is a reasonable thing to weigh, alongside the fact that being early also means access to something that genuinely did not exist for women who cannot take estrogen.

What else reduces hot flashes without hormones?

A prescription is not the only lever, and several of the alternatives have reasonable evidence behind them.

• SSRIs and SNRIs at low doses reduce flush frequency, and paroxetine has a specific FDA approval for the indication. Useful when low mood or anxiety coexists.
• Gabapentin is often used where night sweats dominate, because sedation at bedtime is a feature rather than a problem.
• Cognitive behavioural therapy does not reduce flush frequency much but consistently reduces how bothersome they are, which is the outcome that affects daily life.
• Weight loss, stopping smoking and reducing alcohol all have supporting evidence and no prescription required.
• Cooling strategies address the symptom rather than the cause but are worth having in place; see cooling products.

Supplements marketed for flushes are a different category. Black cohosh has the most study behind it and still produces inconsistent results against placebo, in a symptom where the placebo response reaches 47% in a well-run trial.